
Atopic Dermatitis
Latest News

Latest Videos

CME Content
More News

Patients with moderate-to-severe atopic dermatitis are at high risk of having inadequate disease control, according to a cross-sectional study in JAMA Dermatology.

A 13-year-old girl presented with a history of atopic dermatitis and alopecia totalis. Nine months after starting dupilumab, the patient regrew hair on 60 percent of her scalp.

Severe case of dupilumab-associated conjunctivitis successfully managed without discontinuing therapy.

In this article, Dr. Peter A. Lio discusses how recent advances in atopic dermatitis have led to a new standard of care, which aims to keep patients clear safely and maximize improvements in quality of life.

Adults with severe and mostly active atopic eczema are at a higher risk of developing cardiovascular disease, a population-based study shows.

Physicians bypass systemic treatments in moderate to severe cases of atopic dermatitis despite its potential to control symptoms.

Cosmetic products with prebiotics, probiotics and postbiotics may be beneficial in treating eczema, a physician reported at the Fall Clinical Dermatology Conference held earlier this month in Las Vegas.

Dupilumab-associated conjunctivitis may warrant discontinuing therapy for atopic dermatitis, a study shows.

Atopic dermatitis patients are likely more willing to adhere to treatment and achieve better outcomes when there is shared decision-making between the clinician and patient, according to an article in press in the Annals of Allergy, Asthma and Immunology.

Combination treatment of dupilumab and topical corticosteroid treatment improved itch, mood and quality of life in adult patients with moderate-to-severe atopic dermatitis, according to a new trial.

Multiple burning, painful skin lesions appear on the legs the morning after a walk in the woods. What’s your diagnosis?

A study presented at EADV in Paris today showed that dupilumab met its primary endpoints in a phase three study of adolescents with moderate-to-severe atopic dermatitis.

In this slideshow, we highlight some of the most innovative and important clinical advances in the treatment of atopic dermatitis.

The biologic dupilumab is projected to be a cost-effective treatment for moderate-to-severe atopic dermatitis, shows a new study. (©Dzm1try/Shutterstock.com)

Topical vitamin A provides no benefit in treating atopic dermatitis, whereas topical vitamin D may actually exacerbate symptoms, according to an evidence-based review.

A summary of treatments for atopic dermatitis in children.

Physicians spell out knowns and unknowns associated with treating pediatric atopic dermatitis.

Mapping the human genome for chronic itch holds the potential to develop targeted therapy for atopic dermatitis and psoriasis itch, a study shows.

Study shows that blocking IL-13 improves atopic dermatitis ― a promising finding for IL-13 atopic dermatitis drugs in development.


Patients with moderate-severe atopic dermatitis are at high risk of having inadequate disease control, according to a cross-sectional study in JAMA Dermatology.

Study finds the combination of duplilumab and topical corticosteroids works in hard-to-treat atopic dermatitis cases in adult patients.

FDA approves early, pre-approval trials for pediatric cases

The skin care industry promotes products designed for sensitive skin, yet dermatologists are concerned about the use of skin care products for skin disease.

Observational study shows high heart disease risk in severe and predominantly active atopic eczema.














